A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Seongnam, South Korea Saturday, July 19, 2025, 12:00 Hrs [IST] ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use of two Covid-19 vaccines, newly released documents show.

FDA recognizes uncertainty in COVID-19 booster efficacy; Invivyd plans innovative monoclonal antibody development for prevention and treatment.

Single doses of 150 milligrams (mg), 300 mg, and 450 mg provided 58%, 61%, and 76% protection from symptomatic flu, ...

During COVID-19, many research groups sought to develop drugs that target the external surfaces of Spike proteins shared by coronaviruses, which bind to receptor molecules on the surface of host ...

FDA grants full approval to Moderna's COVID-19 vaccine for children aged 6 months to 11 years with medical vulnerabilities, ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

Kennedy Jr. appeared on the latest episode of Tucker Carlson’s podcast on Monday and it’s filled with the ramblings of a man ...

Invivyd, SPEAR Study Group to assess the effects of monoclonal antibody therapy for recent Covid & Covid-19 post-vaccination syndrome: Waltham, Massachusetts Saturday, July 5, 202 ...